For the year ending 2025-12-31, KNSA had -$17,985K decrease in cash & cash equivalents over the period. $136,417K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 59,005 |
| Depreciation and amortization expense | 1,554 |
| Share-based compensation expense | 37,003 |
| Non-cash lease expense | 3,666 |
| Net amortization (accretion) of discounts on short-term investments | 916 |
| Net (gain) loss on disposal of property and equipment | 120 |
| Deferred income taxes | 13,002 |
| Prepaid expenses and other current assets | 22,481 |
| Accounts receivable, net | -26,130 |
| Inventory | 28,531 |
| Other long-term assets | 1,210 |
| Accounts payable | 142 |
| Accrued expenses, accrued collaboration expenses and other current liabilities | 37,497 |
| Operating lease liabilities | -3,455 |
| Other long-term liabilities | 16,699 |
| Net cash provided by operating activities | 137,985 |
| Purchases of property and equipment | 1,568 |
| Purchases of short-term investments | 386,915 |
| Proceeds from the maturities of short-term investments | 199,490 |
| Net cash provided by (used in) investing activities | -188,993 |
| Proceeds from issuance of class a ordinary shares under incentive award plans and employee share purchase plan | 40,753 |
| Payments in connection with ordinary stock tendered for employee tax obligations | 7,730 |
| Net cash provided by financing activities | 33,023 |
| Net increase (decrease) in cash and cash equivalents | -17,985 |
| Cash and cash equivalents at beginning of period | 183,581 |
| Cash and cash equivalents at end of period | 165,596 |
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)